Indivior UK and C4X Discovery Holdings entered into a license agreement whereby Indivior UK obtained exclusive global rights to develop and commercialize C4X’s oral orexin-1 receptor antagonist program.    The orexin-1 (“OX1”) molecular pathway has been identified by Indivior as a priority pathway for the treatment of addiction. Selective blockade of the OX1 system has been shown to decrease drug-seeking behavior related to psychomotor stimulants, opiates and alcohol, a...